Anti-Neprilysin Market Breakthroughs: Innovations in Heart Health
Posted by Roger on December 18th, 2023
The Anti-Neprilysin market consists of drugs that are used for the treatment of heart failure by inhibiting neprilysin enzyme. Neprilysin is an important enzyme involved in the degradation of natriuretic peptides which help regulate blood pressure and sodium balance. Inhibiting this enzyme helps to preserve natriuretic peptides in the body and provides clinical benefits in heart failure patients. The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The increasing prevalence of heart failure presents a major market opportunity for anti-neprilysin drugs. As per the American Heart Association statistics, over 6 million adults in the United States suffer from heart failure. The incidence of heart failure is rising globally due to aging population and increasing risk factors like diabetes, obesity and cardiac issues. Currently, sacubitril-valsartan is the only approved anti-neprilysin drug for reducing cardiovascular mortality in heart failure patients. However, there is a need for more innovative therapies with improved safety and efficacy profiles. Several pharmaceutical companies are developing new anti-neprilysin compounds which, if approved, can capture a significant market share in the coming years by treating the large heart failure patient pool worldwide.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low for this market as it requires high R&D investments and manufacturing expertise. Additionally, existing players have established brand recognition and strong distribution channels.
Bargaining power of buyers: The bargaining power of buyers is high as there are many existing therapeutic alternatives available for treating heart failure. Buyers can easily switch to substitutes if drug prices increase significantly.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as raw material suppliers have established supply relationships with key manufacturers. However, the development of novel anti-Neprilysin drugs requires specialized synthesis and manufacturing capabilities.
Threat of new substitutes: The threat of new substitutes is high given the ongoing research in developing new therapeutics for treating heart failure with alternate mechanisms of action.
Competitive rivalry: Competition in the market is high among existing players.
SWOT Analysis
Strengths: Growing geriatric population susceptible to heart failure conditions; Unmet medical need for improved heart failure drugs.
Weaknesses: High attrition rates during clinical trials; Strong safety and efficacy data requirements from regulatory agencies.
Opportunities: Potential for label expansions and approvals in new geographic regions; Combination therapies with other drug classes.
Threats: Price control regulations and market access challenges in various countries; Long approval timelines affecting revenue generation.
Key Takeaways
The global anti-Neprilysin market is expected to witness high growth over the forecast period driven by an aging population and rising heart failure prevalence globally. The Americas currently dominate the anti-Neprilysin market owing to high healthcare spending and presence of major players in the region. Europe holds the second largest share and is expected to grow at a steady pace due to healthcare reimbursement and availability of alternative therapies. The Asia Pacific region is anticipated to register fastest growth owing to rising incidence of cardiovascular diseases in China and India coupled with improving access to diagnosis and treatment in these countries.
Key players operating in the anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET and Novartis have established market leadership positions through their anti-Neprilysin drug candidates currently in late stages of clinical trials. Pharmaleads and Theravance Biopharm are also engaged in developing novel compounds for treating heart failure through alternative mechanisms of action. The emergence of these drugs over the forecast period will further intensify market competition.
